Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Venera Miller

Psychiatry Prince Frederick, MD Medical Doctor

NPI 1053349902 CMS profile 274589

242 Merrimac Court, Prince Frederick, MD 20678

Open in the dashboard

General payments

$5,863

335 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Venera Miller of Prince Frederick, MD is reported in the CMS Open Payments database as having received $5,863 across 335 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,555 83
2024 General $1,261 65
2023 General $1,044 59
2022 General $822 50
2021 General $360 19
2020 General $252 16
2019 General $569 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Venera Miller
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Venera Miller were reported at $1,555. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Venera Miller Psychiatry median Middle half National median
2019 $569 $184 $59–$605 $163
2020 $252 $119 $36–$372 $114
2021 $360 $143 $43–$576 $132
2022 $822 $153 $50–$590 $149
2023 $1,044 $170 $56–$651 $160
2024 $1,261 $179 $57–$673 $164
2025 $1,555 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vanda Pharmaceuticals Inc. $1,040 55 payments
  2. AbbVie, Inc. $990 66 payments
  3. ITI, Inc. $859 37 payments
  4. Lundbeck LLC $839 52 payments
  5. Otsuka America Pharmaceutical, Inc. $421 24 payments
  6. Indivior Inc. $399 17 payments
  7. Axsome Therapeutics, Inc. $211 11 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $196 11 payments
  9. Alkermes, Inc. $191 10 payments
  10. Allergan Inc. $161 17 payments
  11. Other $556 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,783 331 payments
  2. Education $80 4 payments
Products named General payments · program years 2019–2025
  1. FANAPT $1,040 55 payments
  2. HETLIOZ $837 43 payments
  3. VRAYLAR Neuroscience $706 47 payments
  4. CAPLYTA Psychiatry $611 24 payments
  5. VRAYLAR Neuroscience $445 36 payments
  6. REXULTI Psychiatry $422 25 payments
  7. REXULTI Psychiatry $421 24 payments
  8. SUBLOCADE $399 17 payments
  9. ABILIFY MAINTENA $307 21 payments
  10. CAPLYTA Psychiatry $248 13 payments
  11. Other $1,917 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

595

Median for Psychiatry & Neurology: 100

Drug cost

$16,169

Median for Psychiatry & Neurology: $2,986

Branded share of claims

6.1%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 19 $4,513
Fluoxetine Hcl Generic 23 $1,661
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $1,592
Lamotrigine Er Lamotrigine Brand 12 $1,488
Olanzapine Generic 16 $679
Lamotrigine Generic 28 $646
Hydroxyzine Hcl Generic 31 $632
Trazodone Hcl Generic 48 $599
Duloxetine Hcl Generic 30 $565
Clonazepam Generic 80 $555

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $368
$368 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $102
  • Lundbeck LLC $71
$173 — —
VRAYLAR
  • AbbVie, Inc. $171
$171 — —
ABILIFY MAINTENA
  • Lundbeck LLC $102
$102 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record